Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain

Completed

Conditions studied: Pain, Chronic, Prescription Drug Abuse (Not Dependent)

In brief

Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce their development.

Key facts

Study ID

NCT03947749

Run by

University of Florida

People needed

275

Starts

2019-09-25

Expected to finish

2023-04-06

Last updated by the study team

2023-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients age ≥18 years with chronic musculoskeletal pain (pain present for 3 or more months) treated with prescription opioids on most days in the past 3 months.

You may not qualify if…

• Patients who are non-English speaking,
• Patients who are incarcerated
• Patients who are unable to provide consent will be excluded.

Where it is running

• UF Health of University of Florida — Gainesville, Florida, United States
• UF Health - Jacksonville — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.